Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma

This study is designed as a multi-center, randomized, open-label trial to evaluate the efficacy of Cerebraca Wafer in patients with recurrent glioblastoma. Cerebraca Wafer is intended for use in recurrent glioblastoma as an adjunct to surgery (followed by standard-of-care temozolomide), demonstrating potential to improve outcomes in this serious and life-threatening condition

NCT Number	NCT07349693
Lead Sponsor	Everfront Biotech Co., Ltd.
Conditions	Recurrent Glioblastoma, IDH-Wildtype
Enrollment	175 participants
Start Date	2026-11-01
Primary Completion	2028-12-01 (estimated)
Study Completion	2030-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-20